Pennsylvania 2025_0 Regular Session Status: In Committee Bipartisan · 9 R · 1 D cosponsors

SB 1215 — An Act amending the act of June 2, 1915 (P.L.736, No.338), known as the Workers' Compensation Act, in liability and compensation, further providing for schedule of compensation.

Last action — Laid on the table (Pursuant to Senate Rule 9), Sept. 29, 2026

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced March 13, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 10 sponsors

    1 primary, 9 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (9 R · 1 D) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

The bill amends the Workers' Compensation Act related to prescription topical drug costs.

This legislation aims to address the high costs associated with prescription topical drugs under workers' compensation. It modifies the schedule of compensation to potentially alleviate excessive expenses for these medications.

What this means for you
  • Workers: This means you may have better access to more affordable prescription topical medications under workers' compensation.

Summary

Addressing Excessive Costs for Prescription Topical Drugs in Workers' Compensation

Bill Text

How this bill changes current law

3 changes Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

The bill establishes specific reimbursement guidelines for compound and noncompound topical drugs under Pennsylvania's Workers' Compensation Act.

  • Section 306(f.1)(3)(vi)

    The reimbursement for any compound drug shall be calculated on a per ingredient basis as determined in accordance with subclause (A). If any individual ingredient does not have a valid and recognized NDC number, the compound drug shall not be reimbursed. The following shall apply: (I) A retail pharmacy, mail order pharmacy or physician shall be reimbursed a single compounding fee of twenty dollars ($20) per prescription filled and dispensed. (II) In no instance shall reimbursement for a compound drug exceed four hundred dollars ($400) per thirty-day supply or a prorated amount if the supply is greater or less than thirty days. (III) A compound drug that is essentially a duplicate of a commercially available drug product is not reimbursable. The status of a compound drug as essentially a duplicate of a commercially available drug product shall be determined pursuant to 21 U.S.C. § 353b (relating to outsourcing facilities).

    Introduces reimbursement rules for compound drugs, including a fee structure and limitations on duplicate drugs.

  • Section 306(f.1)(3)(vi)

    The reimbursement for any noncompound topical drug shall be the lesser of one hundred and ten per centum of the AWP, the Federal Upper Limit as established by the Centers for Medicare and Medicaid Services pursuant to 42 U.S.C. § 1396r-8(e)(4) (relating to payment for covered outpatient drugs) and 42 CFR 447.514 (relating to upper limits for multiple source drugs) or two hundred forty dollars ($240) for a thirty-day supply, prorated if the supply is greater or less than thirty days, plus a single dispensing fee of ten dollars ($10) per prescription.

    Establishes reimbursement guidelines for noncompound topical drugs, including a fee cap and dispensing fee.

  • Section 306(f.1)(3)(vi)

    As used in this subclause: "Compound drug" shall mean a non-Food and Drug Administration approved pharmaceutical preparation that is prescribed by a physician and prepared by a licensed pharmacist or physician by combining, mixing or altering ingredients to tailor a medication to the needs of an individual employe, including when a commercially available Food and Drug Administration-approved drug is not suitable to meet those needs. The term includes, but is not limited to, dermatological agents or topical preparations such as creams, gels, ointments and transdermal patches formulated using bulk ingredients or commercially available products that are combined or altered outside of Food and Drug Administration-approved labeling. "Topical drug" shall mean a drug or medication applied to the skin with intention to provide a localized or systemic result. The term shall include creams, gels, ointments and transdermal patches.

    Defines 'compound drug' and 'topical drug' for clarity in reimbursement contexts.

Action History

  1. Laid on the table (Pursuant to Senate Rule 9), Sept. 29, 2026

  2. First consideration, June 10, 2026

  3. Reported as committed, June 10, 2026

  4. Referred to LABOR AND INDUSTRY, March 13, 2026

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 9 co-sponsors · 243 not signed on

Sponsors (1)

Co-sponsors (9)

Not signed on (243)

243 members have not signed on to this bill.

Show all 243 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare labor health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1215 do?
Addressing Excessive Costs for Prescription Topical Drugs in Workers' Compensation
Who sponsors SB 1215?
SB 1215 is sponsored by Devlin J. Robinson (Republican), Camera Bartolotta (Republican), Elder A. Vogel (Republican), David G. Argall (Republican), Scott E. Hutchinson (Republican), Kristin Phillips-Hill (Republican), Lisa M. Boscola (Democratic), Patrick J. Stefano (Republican), Daniel Laughlin (Republican), and Judy Ward (Republican).
What is the current status of SB 1215?
This bill is in committee in the Senate. Introduced March 13, 2026. It must pass committee before a floor vote.
Where can I track SB 1215?
Track SB 1215 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1215

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 1215

Last checked for changes 7 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →